These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 29451275)

  • 1. Cenegermin for the treatment of neurotrophic keratitis.
    Sacchetti M; Bruscolini A; Lambiase A
    Drugs Today (Barc); 2017 Nov; 53(11):585-595. PubMed ID: 29451275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
    Pflugfelder SC; Massaro-Giordano M; Perez VL; Hamrah P; Deng SX; Espandar L; Foster CS; Affeldt J; Seedor JA; Afshari NA; Chao W; Allegretti M; Mantelli F; Dana R
    Ophthalmology; 2020 Jan; 127(1):14-26. PubMed ID: 31585826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Treatment of a Pediatric Neurotrophic Keratopathy With Cenegermin.
    Papadopoulos K; Besgen V; Sekundo W
    Cornea; 2021 Apr; 40(4):516-518. PubMed ID: 32947402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cenegermin: A Review in Neurotrophic Keratitis.
    Deeks ED; Lamb YN
    Drugs; 2020 Apr; 80(5):489-494. PubMed ID: 32185680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy.
    Hamrah P; Yavuz Saricay L; Ozmen MC
    Cornea; 2022 Jun; 41(6):673-679. PubMed ID: 35266655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and instrumental assessment of the corneal healing in moderate and severe neurotrophic keratopathy treated with rh-NGF (Cenegermin).
    Roszkowska AM; Inferrera L; Aragona E; Gargano R; Postorino EI; Aragona P
    Eur J Ophthalmol; 2022 Nov; 32(6):3402-3410. PubMed ID: 35473440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric Use of Recombinant Human Nerve Growth Factor 20 μg/mL Eye Drops (Cenegermin) for Bilateral Neurotrophic Keratopathy in Congenital Corneal Anesthesia.
    Leto MG; Toro ME; Indemini PE; Fruttero C; Denina M; Dalmazzo C; Sannia A; Vaiano AS
    Cornea; 2021 Feb; 40(2):228-231. PubMed ID: 33201057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the Medical Management of Neurotrophic Keratitis.
    Dohlman TH; Singh RB; Dana R
    Semin Ophthalmol; 2021 May; 36(4):335-340. PubMed ID: 33705259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical cenegermin 0.002% for pediatric neurotrophic keratopathy.
    Elhusseiny AM; Traish AS; Saeed HN; Mantagos IS
    Eur J Ophthalmol; 2022 Nov; 32(6):3420-3424. PubMed ID: 35469461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical outcome and satisfaction survey in patients with neurotrophic keratopathy after treatment with cenegermin eye drops or amniotic membrane transplantation.
    Sacchetti M; Komaiha C; Bruscolini A; Albanese GM; Marenco M; Colabelli Gisoldi RAM; Pocobelli A; Lambiase A
    Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):917-925. PubMed ID: 34633522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy.
    Pedrotti E; Bonacci E; Chierego C; De Gregorio A; Cozzini T; Brighenti T; Caldarella G; Pastore G; Fasolo A; Marchini G
    Orphanet J Rare Dis; 2022 Feb; 17(1):63. PubMed ID: 35189948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotrophic keratopathy.
    Dua HS; Said DG; Messmer EM; Rolando M; Benitez-Del-Castillo JM; Hossain PN; Shortt AJ; Geerling G; Nubile M; Figueiredo FC; Rauz S; Mastropasqua L; Rama P; Baudouin C
    Prog Retin Eye Res; 2018 Sep; 66():107-131. PubMed ID: 29698813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update On Cenegermin Eye Drops In The Treatment Of Neurotrophic Keratitis.
    Sheha H; Tighe S; Hashem O; Hayashida Y
    Clin Ophthalmol; 2019; 13():1973-1980. PubMed ID: 31631965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical treatment with nerve growth factor for neurotrophic keratitis.
    Bonini S; Lambiase A; Rama P; Caprioglio G; Aloe L
    Ophthalmology; 2000 Jul; 107(7):1347-51; discussion 1351-2. PubMed ID: 10889110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops.
    Fausto R; Ceccuzzi R; Micheletti E; Clerici R; Riva I; Katsanos A; Oddone F; Quaranta L
    Medicine (Baltimore); 2020 Jul; 99(30):e20816. PubMed ID: 32791670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aftermarket effects of cenegermin for neurotrophic keratopathy in pediatric patients.
    Hatcher JB; Soifer M; Morales NG; Farooq AV; Perez VL; Shieh C
    Ocul Surf; 2021 Jul; 21():52-57. PubMed ID: 33887453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?
    Bruscolini A; Marenco M; Albanese GM; Lambiase A; Sacchetti M
    Orphanet J Rare Dis; 2022 Feb; 17(1):57. PubMed ID: 35172847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
    Bonini S; Lambiase A; Rama P; Sinigaglia F; Allegretti M; Chao W; Mantelli F;
    Ophthalmology; 2018 Sep; 125(9):1332-1343. PubMed ID: 29653858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current and experimental treatment approaches for neurotrophic keratopathy].
    Alder J; Mertsch S; Menzel-Severing J; Geerling G
    Ophthalmologe; 2019 Feb; 116(2):127-137. PubMed ID: 30707284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human recombinant nerve growth factor (Cenegermin) in a patient affected by primary congenital glaucoma with neurotrophic keratopathy.
    Riva I; Micheletti E; Fausto R; Bruttini C; De Angelis G; Ceccuzzi R; Quaranta L
    Eur J Ophthalmol; 2022 Jul; 32(4):NP78-NP81. PubMed ID: 33657894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.